about
Validation of genetically matched wild-type strain and lysyl oxidase-like 1 knockout mouse model of pelvic organ prolapseImpact of parturition on chemokine homing factor expression in the vaginal distention model of stress urinary incontinence.Animal models of female pelvic organ prolapse: lessons learned.Bladder cancer in 2014: From the genomic frontier to immunotherapeutics.Adjuvant therapy for high-risk localized kidney cancer- emerging evidence and future clinical trials.Immunotherapy for the Treatment of Urothelial Carcinoma.Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.Effect of Pregnancy and Delivery on Cytokine Expression in a Mouse Model of Pelvic Organ Prolapse.Regionalization of Cystectomy: Importance of Care Coordination, Bundled Payments and Surgical Ownership.Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.Trends in urinary diversion after radical cystectomy for urothelial carcinoma.Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinomaContinuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-CPatterns of hardware related electrode failures in sacral nerve stimulation devicesOverall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapyThe association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomyCytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survivalVariation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?
P50
Q34139558-6FB64F43-7074-46DA-9905-0BDBFC8E4E98Q35249157-B8D04E6A-78B9-4AD5-BDA0-275F2908A196Q36029982-263F0DE8-8A0D-44A2-A81C-940C9C7A5319Q38307285-31C76D32-35CA-4A9F-9314-76B9E267B665Q38686841-BC258775-D4D7-45CC-9ECB-A6D1CB207826Q38909251-3667B746-F865-4E90-8F87-170A7431ED19Q39586831-4DE2C9CE-633B-4340-B0EF-A28B22D6D591Q40279075-3EE46B19-F927-457A-B4EA-94504D912554Q41703559-4CFD51C6-2E37-429C-A523-939226706503Q44790005-8855751D-D558-4017-9E15-74492309CC25Q46142613-E610EA08-22DA-4AC8-9C0C-A3E4C6A27AD6Q46418912-3FF304F4-81C0-4142-A34D-9A80B181109AQ46767539-98EA735B-C9E3-47EC-8C59-995FE856C0E3Q46918880-3591AF43-6902-4079-B9F2-4966887128F6Q47211582-292A8A6D-02DF-4CBA-8E87-12A3866E37B4Q50058314-C4143DDF-D6E2-4459-9452-F0D6CDFA41BEQ50077610-9C188086-4072-4AF2-8513-032442102C25Q52632425-9B8BFE26-725D-4ECE-8661-47D5B6A1A3CAQ57157049-EDAA147F-EF24-4874-9C38-C592797D9D2DQ57790263-27D07BD8-C0DE-4F8F-8FC6-D5A4383D23C8Q85892109-739CB2FC-D75C-44F8-ADF6-9C4F78159CD4Q88646235-DEE35072-2544-4F82-B175-FE1924873158Q89770695-C88DF5FA-28B7-4BA9-ACA1-055734DA6322Q92727675-3E05A463-6CC7-4CCC-92AA-006E5C70A3CBQ93182682-8036CFE8-1D8B-42B0-95BE-BCE63150FDAB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew T Lenis
@ast
Andrew T Lenis
@en
Andrew T Lenis
@es
Andrew T Lenis
@nl
type
label
Andrew T Lenis
@ast
Andrew T Lenis
@en
Andrew T Lenis
@es
Andrew T Lenis
@nl
prefLabel
Andrew T Lenis
@ast
Andrew T Lenis
@en
Andrew T Lenis
@es
Andrew T Lenis
@nl
P106
P1153
57191779504
P31
P496
0000-0001-9413-7793